Clinical Risk Stratification Optimizes Value of Biomarkers to Predict New-Onset Heart Failure in a Community-Based Cohort
Why the study?
Does biomarker testing improve risk prediction for new-onset heart failure in a community-based cohort?
Population
8569 HF-free participants in the Prevention of Vascular and Renal Endstage Disease cohort, categorized into…
Design
Cohort
Authors
Discussion
Loading...
Member takes
Implication
Should not yet change practice; extends multi-biomarker prediction evidence but leaves open prospective outcome validation.
Structured PICO
Does biomarker testing improve risk prediction for new-onset heart failure in a community-based cohort?
P
Population
8569 HF-free participants in the Prevention of Vascular and Renal Endstage Disease cohort (mean age 49 years, 50% men), categorized into low-risk (n=6915) and high-risk (n=1654) groups based on cardiovascular history.
I
Intervention
Measurement of 13 biomarkers reflecting diverse pathophysiologic domains (including natriuretic peptides, troponin-T, urinary albumin excretion)
O
Outcome
Incident new-onset heart failure (including HFrEF and HFpEF)hard clinical
Routine biomarker testing with natriuretic peptides and troponin-T improves risk prediction for new-onset heart failure, particularly HFrEF, in patients with increased cardiovascular risk.
Cite This Study
Brouwers et al. (2014) studied this question.